SLAMF7 and neoplasm: In preclinical studies, SLAMF7 CAR-T cells showed strong anti-tumor effects against both MM cell lines and primary myeloma cells and prolonged the survival of mice with human MM.1S and IM9 myeloma cell xenografts [57].